Fanlization
04-10
这篇文章不错，转发给大家看看
Kintara (KTRA) Stock Soars on Merger Agreement With TuHURA
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":293812433965240,"tweetId":"293812433965240","gmtCreate":1712762161740,"gmtModify":1712762163366,"author":{"id":4095630847582090,"idStr":"4095630847582090","authorId":4095630847582090,"authorIdStr":"4095630847582090","name":"Fanlization","avatar":"https://static.tigerbbs.com/4ff33c5fed6426a68a814ef72a46d188","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":3,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":2,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"html":"<html><head></head><body>这篇文章不错，转发给大家看看</body></html>","htmlText":"<html><head></head><body>这篇文章不错，转发给大家看看</body></html>","text":"这篇文章不错，转发给大家看看","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/293812433965240","repostId":2425310589,"repostType":2,"repost":{"id":"2425310589","kind":"highlight","pubTimestamp":1712241480,"share":"https://www.laohu8.com/m/news/2425310589?lang=&edition=full","pubTime":"2024-04-04 22:38","market":"us","language":"en","title":"Kintara (KTRA) Stock Soars on Merger Agreement With TuHURA","url":"https://stock-news.laohu8.com/highlight/detail?id=2425310589","media":"Zacks","summary":"Kintara Therapeutics, Inc.’s KTRA shares surged 63.4% on Apr 3 after the company inked a definitive merger agreement with Florida-based privately-held company, TuHURA Biosciences Inc. Per the agreement, KTRA will merge into TuHURA to form a new company aimed at developing late-stage oncology candidates.The combined company will operate under the name of TuHURA Biosciences, Inc., and trade in the Nasdaq stock exchange under the ticker symbol \"HURA.\". Per the agreement, Kintara equity holders are expected to collectively own up to approximately 2.85%, or 5.45%, including shares underlying the contingent value rights of the common stock of the combined company on a pro forma fully diluted basis. Meanwhile, equity holders of TuHURA are eligible to collectively own approximately 97.15%, or 94.55%, taking the distribution of the CVR shares, of the common stock of the combined company on a pro forma fully diluted basis after the merger is completed.The newly formed company will focus on adva","content":"<html><body><p><strong><a href=\"https://laohu8.com/S/KTRA\">Kintara Therapeutics, Inc.</a></strong>’s KTRA shares surged 63.4% on Apr 3 after the company inked a definitive merger agreement with Florida-based privately-held company, TuHURA Biosciences Inc. Per the agreement, KTRA will merge into TuHURA to form a new company aimed at developing late-stage oncology candidates.</p>\n<p>The combined company will operate under the name of TuHURA Biosciences, Inc., and trade in the Nasdaq stock exchange under the ticker symbol \"HURA.\"</p>\n<p>The transaction has been approved by the boards of directors of both companies and is expected to close in the third quarter of 2024, subject to customary closing conditions.</p>\n<p>Per the agreement, Kintara equity holders are expected to collectively own up to approximately 2.85%, or 5.45%, including shares underlying the contingent value rights (CVR) of the common stock of the combined company on a pro forma fully diluted basis. Meanwhile, equity holders of TuHURA are eligible to collectively own approximately 97.15%, or 94.55%, taking the distribution of the CVR shares, of the common stock of the combined company on a pro forma fully diluted basis after the merger is completed.</p>\n<p>The newly formed company will focus on advancing TuHURA's personalized cancer vaccine and first-in-class bi-functional antibody-drug conjugates (ADCs) to overcome the hurdles in the treatment of cancer with existing immunotherapies.</p>\n<p>ADCs are being considered a disruptive innovation in the pharmaceutical industry as these will allow better treatment of cancer by harnessing the targeting power of antibodies to deliver cytotoxic molecule drugs to tumors.</p>\n<p>Shares of Kintara have lost 3.3% year to date against the industry’s growth of 1.9%.</p>\n<p><img src=\"https://s1.yimg.com/uu/api/res/1.2/zBkN1feR85cSNmi8u7lm6Q--/cT03NTthcHBpZD15dmlkZW9mZWVkczs-/https://media.zenfs.com/en/zacks.com/6416afa85f382eca776c9ed90bea040a\"/><br/><span>Image Source: Zacks Investment Research</span><br/></p>\n<p>KTRA is developing its lead pipeline candidate, REM-001, a second-generation photodynamic therapy photosensitizer agent for the treatment of cutaneous metastatic breast cancer.</p>\n<p>Meanwhile, TuHURA is developing its lead personalized cancer vaccine candidate, IFx-2.0, to overcome primary resistance to checkpoint inhibitors.</p>\n<p>TuHURA is planning to initiate a phase III registration study evaluating IFx-2.0 administered as an adjunctive therapy to <strong>Merck</strong>’s MRK blockbuster cancer drug, Keytruda (pembrolizumab), for the first-line treatment of advanced merkel cell carcinoma.</p>\n<p>Merck’s biggest revenue generator, Keytruda, is approved for treating several cancer indications. Sales of Keytruda came in around $25 billion in 2023.</p>\n<p>MRK continues to evaluate Keytruda in combination studies for various other indications.</p>\n<p>Enrollment in the placebo-controlled phase III study is expected to begin in the second half of 2024. The study is likely to be conducted under the FDA's Accelerated Approval Pathway, which helps in earlier approval of drugs that address serious and unmet medical conditions.</p>\n<p>Along with the latest merger agreement, TuHURA is making $31 million subscribed financing, which is expected to fund the combined company’s operations through late 2025.</p>\n<p>The transaction should create a near and long-term value for Kintara’s shareholders as the newly formed company will be well-positioned to develop groundbreaking new therapies for treating cancer.</p>\n<h3>Zacks Rank & Stocks to Consider</h3>\n<p>Kintara currently carries a Zacks Rank #4 (Sell).</p>\n<p>Some better-ranked stocks in the healthcare sector are <strong>Ligand Pharmaceuticals Incorporated</strong> LGND and <strong><a href=\"https://laohu8.com/S/ANIP\">ANI Pharmaceuticals, Inc.</a></strong> ANIP, each flaunting a Zacks Rank #1 (Strong Buy) at present. You can see <strong>the complete list of today’s Zacks #1 Rank stocks here</strong>.</p>\n<p>In the past 60 days, estimates for Ligand’s 2024 earnings per share have improved from $4.42 to $4.56. Year to date, LGND shares have gained 4.5%.</p>\n<p>Earnings of LGND beat estimates in each of the trailing four quarters, the average surprise being 84.81%.</p>\n<p>In the past 60 days, estimates for ANI Pharmaceuticals’ 2024 earnings per share have improved from $4.06 to $4.43. Year to date, ANIP shares have jumped 21.7%.</p>\n<p>Earnings of ANIP beat estimates in each of the trailing four quarters, the average surprise being 109.06%.</p>\n<p>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report</p>\n<p>Merck & Co., Inc. (MRK) : Free Stock Analysis Report</p>\n<p>Ligand Pharmaceuticals Incorporated (LGND) : Free Stock Analysis Report</p>\n<p>ANI Pharmaceuticals, Inc. (ANIP) : Free Stock Analysis Report</p>\n<p>Kintara <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>, Inc. (KTRA) : Free Stock Analysis Report</p>\n<p>To read this article on Zacks.com click here.</p>\n<p>Zacks Investment Research</p></body></html>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Kintara (KTRA) Stock Soars on Merger Agreement With TuHURA</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nKintara (KTRA) Stock Soars on Merger Agreement With TuHURA\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-04-04 22:38 GMT+8 <a href=https://finance.yahoo.com/news/kintara-ktra-stock-soars-merger-143800928.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Kintara Therapeutics, Inc.’s KTRA shares surged 63.4% on Apr 3 after the company inked a definitive merger agreement with Florida-based privately-held company, TuHURA Biosciences Inc. Per the ...</p>\n\n<a href=\"https://finance.yahoo.com/news/kintara-ktra-stock-soars-merger-143800928.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://s.yimg.com/uu/api/res/1.2/H9DYdttPy00EKBHhcxtlCA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9f2a2e04a053cda7a8c096e532e43d28","relate_stocks":{"LU0058720904.USD":"联博国际健康护理基金A","SG9999014559.SGD":"United Income Focus Trust Dis SGD","LU2361044949.HKD":"WELLINGTON US QUALITY GROWTH \"A\" (HKD) ACC","LGND":"Ligand Pharmaceuticals Inc.","LU1066051498.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (USD) INC","LU2361044865.SGD":"WELLINGTON US QUALITY GROWTH \"A\" (SGDHDG) ACC","ANIP":"ANI Pharmaceuticals, Inc.","LU1066053197.SGD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM3\" (SGDHDG) INC","SG9999014567.USD":"UOB UNITED INCOME FOCUS TRUST FUND (USD) ACC","BK4161":"工业机械","LU0122379950.USD":"贝莱德世界健康科学A2","LU0965509283.SGD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (SGDHDG) INC","IE00B1BXHZ80.USD":"Legg Mason ClearBridge - US Appreciation A Acc USD","LU2361045086.USD":"WELLINGTON US QUALITY GROWTH \"A\" (USD) ACC","BK4139":"生物科技","SG9999015358.SGD":"United Income Focus Trust Dis SGD-H","BK4534":"瑞士信贷持仓","BK4585":"ETF&股票定投概念","BK4533":"AQR资本管理(全球第二大对冲基金)","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","CVR":"芝加哥机械","SG9999015341.SGD":"United Income Focus Trust Acc SGD-H","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","SG9999014542.SGD":"United Income Focus Trust Acc SGD","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","SG9999001440.SGD":"United Global Dividend Equity Fund A SGD Dist","SG9999001176.USD":"United Global Healthcare Acc USD","LU1585245621.USD":"EASTSPRING INV GLOBAL LOW VOLATILITY EQUITY FUND \"A\" (USD) ACC B","LU0211331839.USD":"FRANKLIN MUTUAL GLB DISCOVERY \"A\" (USD) ACC","IE00BLSP4239.USD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis USD Plus","IE00BLSP4452.SGD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis SGD-H Plus","LU1917777945.USD":"安联专题基金Cl AT Acc","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","BK4588":"碎股","LU1989771016.USD":"东方汇理环球老龄化投资基金 A2 Acc","SG9999014575.USD":"UOB UNITED INCOME FOCUS TRUST FUND (USDHDG) INC","SG9999001176.SGD":"UOB UNITED GLOBAL HEALTHCARE \"SGD\" (ACC)","LU1989772840.SGD":"CPR Invest - Climate Action A2 Acc SGD-H","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","LU2461242641.AUD":"WELLINGTON US QUALITY GROWTH \"A\" (AUDHDG) ACC","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LU0208291251.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) INC","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU1989772923.USD":"CPR Invest - Climate Action A2 Acc USD-H","MRK":"默沙东","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","LU2023250843.SGD":"Allianz Thematica Cl AT Acc H2-SGD","IE00BBT3K403.USD":"LEGG MASON CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A(USD) ACC"},"source_url":"https://finance.yahoo.com/news/kintara-ktra-stock-soars-merger-143800928.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2425310589","content_text":"Kintara Therapeutics, Inc.’s KTRA shares surged 63.4% on Apr 3 after the company inked a definitive merger agreement with Florida-based privately-held company, TuHURA Biosciences Inc. Per the agreement, KTRA will merge into TuHURA to form a new company aimed at developing late-stage oncology candidates.\nThe combined company will operate under the name of TuHURA Biosciences, Inc., and trade in the Nasdaq stock exchange under the ticker symbol \"HURA.\"\nThe transaction has been approved by the boards of directors of both companies and is expected to close in the third quarter of 2024, subject to customary closing conditions.\nPer the agreement, Kintara equity holders are expected to collectively own up to approximately 2.85%, or 5.45%, including shares underlying the contingent value rights (CVR) of the common stock of the combined company on a pro forma fully diluted basis. Meanwhile, equity holders of TuHURA are eligible to collectively own approximately 97.15%, or 94.55%, taking the distribution of the CVR shares, of the common stock of the combined company on a pro forma fully diluted basis after the merger is completed.\nThe newly formed company will focus on advancing TuHURA's personalized cancer vaccine and first-in-class bi-functional antibody-drug conjugates (ADCs) to overcome the hurdles in the treatment of cancer with existing immunotherapies.\nADCs are being considered a disruptive innovation in the pharmaceutical industry as these will allow better treatment of cancer by harnessing the targeting power of antibodies to deliver cytotoxic molecule drugs to tumors.\nShares of Kintara have lost 3.3% year to date against the industry’s growth of 1.9%.\nImage Source: Zacks Investment Research\nKTRA is developing its lead pipeline candidate, REM-001, a second-generation photodynamic therapy photosensitizer agent for the treatment of cutaneous metastatic breast cancer.\nMeanwhile, TuHURA is developing its lead personalized cancer vaccine candidate, IFx-2.0, to overcome primary resistance to checkpoint inhibitors.\nTuHURA is planning to initiate a phase III registration study evaluating IFx-2.0 administered as an adjunctive therapy to Merck’s MRK blockbuster cancer drug, Keytruda (pembrolizumab), for the first-line treatment of advanced merkel cell carcinoma.\nMerck’s biggest revenue generator, Keytruda, is approved for treating several cancer indications. Sales of Keytruda came in around $25 billion in 2023.\nMRK continues to evaluate Keytruda in combination studies for various other indications.\nEnrollment in the placebo-controlled phase III study is expected to begin in the second half of 2024. The study is likely to be conducted under the FDA's Accelerated Approval Pathway, which helps in earlier approval of drugs that address serious and unmet medical conditions.\nAlong with the latest merger agreement, TuHURA is making $31 million subscribed financing, which is expected to fund the combined company’s operations through late 2025.\nThe transaction should create a near and long-term value for Kintara’s shareholders as the newly formed company will be well-positioned to develop groundbreaking new therapies for treating cancer.\nZacks Rank & Stocks to Consider\nKintara currently carries a Zacks Rank #4 (Sell).\nSome better-ranked stocks in the healthcare sector are Ligand Pharmaceuticals Incorporated LGND and ANI Pharmaceuticals, Inc. ANIP, each flaunting a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.\nIn the past 60 days, estimates for Ligand’s 2024 earnings per share have improved from $4.42 to $4.56. Year to date, LGND shares have gained 4.5%.\nEarnings of LGND beat estimates in each of the trailing four quarters, the average surprise being 84.81%.\nIn the past 60 days, estimates for ANI Pharmaceuticals’ 2024 earnings per share have improved from $4.06 to $4.43. Year to date, ANIP shares have jumped 21.7%.\nEarnings of ANIP beat estimates in each of the trailing four quarters, the average surprise being 109.06%.\nWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report\nMerck & Co., Inc. (MRK) : Free Stock Analysis Report\nLigand Pharmaceuticals Incorporated (LGND) : Free Stock Analysis Report\nANI Pharmaceuticals, Inc. (ANIP) : Free Stock Analysis Report\nKintara Therapeutics, Inc. (KTRA) : Free Stock Analysis Report\nTo read this article on Zacks.com click here.\nZacks Investment Research","news_type":1},"isVote":1,"tweetType":1,"viewCount":749,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":27,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/293812433965240"}
精彩评论